Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,912 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension Clear all
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

NCT00171405
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Stretching Training on Arterial Function and Autonomic Control

NCT01741766
View directory record Official record
Conditions
Obesity, Pre-hypertension, Hypertension
Interventions
Stretching Training
Other
Lead sponsor
Florida State University
Other
Eligibility
50 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 2 Interventional

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

NCT01481051
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension (OH)
Interventions
Latanoprost-PPDS
Drug
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Artesia, California • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 31, 2026, 10:25 PM EDT
Not listed Phase 2 Interventional

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

NCT02174991
View directory record Official record
Conditions
Glaucoma
Interventions
Rho-Kinase Inhibitor (AR-12286)
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 31, 2026, 10:25 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

'Ai Pono Cooking Demonstrations

NCT06526650
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions
'Ai Pono
Other
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
1,780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Honolulu, Hawaii • Kapolei, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 31, 2026, 10:25 PM EDT
Not yet recruiting Phase 2 Interventional

VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study

NCT07891182
View directory record Official record
Conditions
Glaucoma
Interventions
Aflibercept Injection, Ahmed Tube Surgery
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 10:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Detection of Glaucoma Using Pupillography

NCT01462526
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
798 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 31, 2026, 10:25 PM EDT
Withdrawn Not applicable Interventional

Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health

NCT02137408
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Docosahexaenoic acid 200 mg, Docosahexaenoic acid 1000 mg
Dietary Supplement · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

NCT03624010
View directory record Official record
Conditions
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Stanford, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery

NCT01404910
View directory record Official record
Conditions
Preeclampsia
Interventions
Apheresis using Liposorber LA-15 System
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Medication Adherence in Hypertension Study

NCT00688350
View directory record Official record
Conditions
Hypertension
Interventions
Behavioral feedback
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
60 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 31, 2026, 10:25 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Pilocarpine After Combined Cataract/Trabectome Surgery

NCT04005079
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Pilocarpine, Ofloxacin, Prednisolone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 1 Interventional

MSC for Occlusive Disease of the Kidney

NCT01840540
View directory record Official record
Conditions
Atherosclerotic Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Hypertension
Interventions
Arterial infusion of autologous mesenchymal stem cells
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 31, 2026, 10:25 PM EDT
Recruiting No phase listed Observational

Global Paradise System US Post Approval Study

NCT06297291
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Paradise Ultrasound Renal Denervation Treatment
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

NCT02070991
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Louisville, Kentucky • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 4 Interventional Results available

Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)

NCT00887510
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Delivering a Digital Health Intervention to Improve Food Access and Dietary Quality Among Adults With Hypertension

NCT06743191
View directory record Official record
Conditions
Hypertension
Interventions
Access Nourish
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 31, 2026, 10:25 PM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

NCT00294710
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Phase 4 Interventional

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

NCT00170924
View directory record Official record
Conditions
Diastolic Dysfunction, Hypertension
Interventions
Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years and older
Enrollment
317 participants
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Not applicable Interventional Results available

Technology Coaching Intervention for Black Women With Hypertension

NCT03577990
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Interactive Technology Enhanced Coaching (ITEC), Interactive Technology-No Coaching (IT)
Behavioral
Lead sponsor
University of North Carolina, Charlotte
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 31, 2026, 10:25 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The International Collaborative Exfoliation Syndrome Treatment Study

NCT00804115
View directory record Official record
Conditions
Exfoliation Syndrome, Glaucoma, Ocular Hypertension
Interventions
Latanoprost with Pilocarpine vs Timolol or Cosopt
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2008 · Synced Oct 31, 2026, 10:25 PM EDT
Completed Not applicable Interventional

Cut Your Pressure Too: The Los Angeles Barbershop Blood Pressure Study

NCT02321618
View directory record Official record
Conditions
Hypertension
Interventions
BP measurement & pharmacy, BP educational materials
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 79 Years · Male only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 31, 2026, 10:25 PM EDT